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Abstract
Pseudoxanthoma elasticum (PXE), caused by mutations in the ABCC6 gene, demonstrates
progressive build-up of calcium phosphate and proteoglycans in the skin, eye, and arteries, and is
associated to myocardial infarctions, stroke, blindness and elevated carotid intima-media thickness
(CIMT). Although CIMT reduction with magnesium (Mg) has been documented in a mouse
model for PXE (Abcc6−/−), it is not clear if Mg is effective in humans with PXE to reduce CIMT.
To examine this, we calculated the rate of change of CIMT (washout) in 15 month and 12-month-
old Abcc6−/− mice fed standard rodent diet with or without Mg supplementation for 2 months.
Using means in untreated 15-month and 12-month-old Abcc6−/− mice (145 μm and 120 μm,
respectively), the rate of change was 8.3 μm/month. Using means in treated 15-month and 12-
month-old Abcc6−/− mice (118 um and 104.6 um, respectively), the rate of change was 4.5 μm.
Compared to normal progression of CIMT in humans without PXE, PXE has advanced
atherosclerosis and possibly a higher CIMT rate of change. This experiment may portend, at least
in PXE, the rationale for a one-year oral Mg CIMT clinical trial and may be useful for application
in other progressive mineralizing disorders, like atherosclerosis.
Introduction
Pseudoxanthoma elasticum, PXE, caused by mutations in the ABCC6 gene affects 1 100,000
to 1 in 25,000 individuals world-wide 1 and demonstrates progressive build-up of calcium
phosphate and proteoglycans in the skin, eye, and arteries, and is consequently associated to
myocardial infarctions, stroke, blindness and elevated carotid intima-media thickness
(CIMT), a biomarker for cardiovascular morbidity and mortality 2–4. Although CIMT
reduction after pharmaceutical intervention has been documented in the literature 5–7, CIMT
return to pathological baseline in progressive mineralizing disorders, especially in Abcc6−/−
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mice, has not been elucidated. Recently, in a mouse model of PXE, a magnesium (Mg)-
enriched diet prevented mineralization of the vibrissae capsule, an early biomarker for
PXE 8, 9, as well as significantly reduced CIMT in Abcc6 −/− mice compared to controls 10.
This study aims to calculate the temporal relationship for CIMT to return to pathological
baseline once Mg, a pharmaceutical intervention that significantly reduced CIMT in
Abcc6 −/− mice 10, is withdrawn. This data may be useful for application in other
progressive mineralizing disorders, like atherosclerosis and may serve a greater role in
understanding the length of time required for Mg to cause reversal change at the level of the
carotid artery that is detectable and significant.
Methods
CIMT was measured in 15 month-old Abcc6 −/− mice fed either standard rodent diet with or
without Mg oxide supplementation (1.85grams/100grams food) for two months, followed by
an additional two months of standard rodent diet. Carotid arteries were harvested from each
panel and paraffin-embedded on numbered cassettes in a blinded fashion. Starting from the
carotid bifurcation, the slides were H&E stained at 1000 μm, 3000 μm and 5000 μm) 10.
Slides were read using 40x magnification on a Nikon Eclipse TE 2000-U microscope
(Mellville, NY, USA) and interpreted with calibrated Image-Pro Plus software (version
6.1.0.346 for Windows 2000/XP professional, Media Cybernetics, Inc., Bethesda, MD) 10.
Approval by Thomas Jefferson University’s Institutional Animal Care and Use Committee
prior to the start of these experiments was obtained. The mean of the CIMT measurements at
1000 μm, 3000 μm and 5000 μm mark distal to the bifurcation were used in the statistical
analysis; each mouse’s CIMT was then averaged to represent the final CIMT measurement
from the treated or untreated Abcc6 −/− group 10. Values from both treated and untreated
groups were analyzed for normal distribution using Hamilton’s test. To determine the
statistical significance between the treated and untreated groups of mice, a two-tailed
Student’s t-test was used 10. To obtain the CIMT value in the 12 month-old mice, Abcc6−/−
and Abcc6+/+ mice were fed either standard rodent diet with or without the same amount of
Mg oxide supplementation for two months and the same histology and statistical analysis
were performed 10. This was done in a previous experiment but a portion was reported here
for fluency and comparison with the new data from the 15-month old mice. (Fig. 1a–d).
Results
As was anticipated, the baseline CIMT in all the control groups were increased with time
(Fig 1a,b,e). (e) The CIMT in the untreated groups was 146 μm in 15-month old Abcc6 −/−
mice (mean, 145 μm, SD 7.12, p<0.001) compared to (b) 114 μm in 12 month-old Abcc6 −/−
mice (mean, 120 μm) 10 ; using means, this results in a calculated rate of change for the
untreated group of 8.3 μm/month. In the Mg-treated group, (f), the actual CIMT of 119 μm
(mean, 118 μm, SD 4.95, p<0.011), was similar to that of the (b) 12 month-old Abcc6 −/−
untreated group, (mean 120 μm, p<0.001). Also, the CIMT in the treated KO group was 90.5
μm (mean 104.6 μm) 10 (d); using means, this results in a calculated rate of change for the
treated group of 4.5 μm/month (Fig. 1).
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Discussion
While Mg reduces CIMT in a mouse model for PXE 10, the notion of whether Mg could be
used in humans with PXE to reduce a known biomarker of morbidly and mortality, and for
how long to be effective, is not so clear. This Mg washout experiment was required to help
answer this quandary. According to the Cardiovascular Health Study and Northern
Manhattan Study, normal CIMT ranges vary from 0.7 – 0.9 mm in 45 to 75 year-olds
humans 11 and the progression of CIMT, depending on risk factors, can range from 0.01 ±
0.05 mm/year 12. Although we used Abcc6−/− mice, humans with PXE have elevated CIMT
compared to controls 4. PXE, a progressive mineralizing disorder can also have advanced
atherosclerosis, explaining the rate of change in CIMT in these mice. With Mg
administration, the rate of change of CIMT per month was much less (4.8 um) versus
without Mg (8.3 um), thus Mg may be useful for reducing CIMT in a rather rapid, short
period of time if administered to PXE patients.
Conclusion
While some trials indicate that CIMT-reducing agents, like statins, may require five years to
see any effect on CIMT in humans 6, this experiment may portend, at least in PXE, the
rationale for a one-year oral Mg CIMT clinical trial. The time required for such CIMT
changes to be evident and significant to reduce morbidity and mortality may be rapid in
PXE.
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Figure 1.
Oral magnesium administration reduced CIMT in Abcc6−/− mice, and the rate of CIMT
change is measurable in this mineralizing disorder. (a) 12 month-old carotid artery section
from wild type (WT, Abcc6+/+) controls (untreated) 10; (b) 12 month-old carotid artery
section from knockout (KO) controls (untreated) (p<0.009 compared to (a)) 10; (c) 12
month-old carotid artery section from WT treated; (d) 12 month-old carotid artery section
from KO treated with 2 months of oral magnesium (p<0.02 compared to (b)) 10; (e) 15
month-old carotid artery section from a KO control mouse (untreated); (f) 15 month-old
carotid artery section from KO mouse treated 2 months on, 2 months off with magnesium
(p<0.011 compared to (e)). The mean value in (f), 118 μm, as well as the individual value
shown, 119 μm, were similar to that of (b), the 12 month-old Abcc6 −/− untreated group,
mean 120 μm. The bar represents 100 μm.
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